-
Feb 272025Drug synthesis route Vafseo (vadadustat)
Vafseo (vadadustat) Vadadustat, developed by Akebia Therapeutics, is an oral hypoxiainducible factor prolyl hydroxylase inhibitor, which was approved
-
Feb 262025The birth and significance of the new drug Emblaveo
On February 4, 2025, the US Food and Drug Administration (FDA) approved Emblaveo, a compound antibiotic developed by AbbVie, in combination with metro
-
Feb 252025Gilead's breakthrough long-acting HIV therapy receives accelerated review in ...
Gilead Sciences announced today that the European Medicines Agency (EMA) has accepted the company's marketing authorization application (MAA) for
-
Feb 242025The first one! FDA approves the listing of 'old drugs'
On February 22, 2025, the US FDA approved the marketing of Ctexli (chenodiol) under Mirum Pharmaceuticals for the treatment of adult cerebral chordoma
-
Feb 212025The latest research on Roche's heavyweight small molecule drugs has been publ...
Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that may be affected before the child is born. The most severe cases, if left
-
Feb 202025Crossing the blood-brain barrier, 93% disease control rate! Breakthrough anti...
Boehringer Ingelheim announced today that the US FDA has accepted a new drug application (NDA) submitted for the small molecule drug zongerinib (BI 18
-
Feb 132025The new mechanism of autoimmune disease therapy has relieved symptoms in near...
AnaptysBio announced today that the investigational therapy rosnilimab has achieved positive top line results in the phase 2b clinical trial RENOIR fo
-
Feb 112025Breakthrough small molecule therapy is about to submit its application for ma...
Boehringer Ingelheim announced today that its investigational therapy, nerandomilast, achieved the primary endpoint in the phase 3 clinical trial FIBR
-
Feb 10202523 innovative drug companies complete a new round of financing
As of January 31, 2025, a total of 180 financing activities have been completed in the global biopharmaceutical field, and the cumulative publicly dis
-
Feb 072025Roche: Completely abandon TIGIT
On January 30, 2025, Roche released its 2024 financial report and updated its research and development pipeline. It is worth noting that Roche has com
-
Feb 062025Science sub issue: This inert gas can improve symptoms of Alzheimer's disease
Alzheimer's disease (AD) is one of the most widely affecting neurological disorders today, with the World Health Organization estimating that the
-
Jan 252025Weight loss of 22% in 36 weeks! Novo Nordisk's latest results on next-generat...
Novo Nordisk announced today the main results of a phase 1b/2a clinical trial of its weekly subcutaneous injection of the single-molecule glucagon lik

